Inflammatory Bowel Disease Monitor

» Advanced search

Paper of the Month - March, 2011

• View Archive »

  • Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn’s mucosa through modulation of antioxidant defense machinery - May, 2012
    Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial - April, 2012
    Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study - March, 2012
    Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis – additional results from two controlled studies - February, 2012
    Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis - January, 2012
    Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study - December, 2011
    Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study - November, 2011
    Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease - October, 2011
    Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis - September, 2011
    3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial - August, 2011
    Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study - July, 2011
    Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? - June, 2011
    Genetics in twins with Crohn’s disease: less pronounced than previously believed? - May, 2011
    Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease - April, 2011
    The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains - March, 2011
    A population-based study of health-care resource use among infliximab users - February, 2011
    Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts - January, 2011
    Clinical utility of measuring infliximab and human antichimeric antibody concentrations in patients with inflammatory bowel disease - December, 2010
    Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis - November, 2010
    Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology - October, 2010
    Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males - September, 2010
    Infliximab, azathioprine, or combination therapy for Crohn’s disease - August, 2010
    Genome-wide association identifies multiple ulcerative colitis susceptibility loci - July, 2010
    Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse - June, 2010
    Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis - May, 2010
    Crohn’s disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly - April, 2010
    Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines - March, 2010
    Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab - February, 2010
    Paediatric inflammatory bowel disease during a 44-year period in Copenhagen County: occurrence, course and prognosis – a population-based study from the Danish Crohn Colitis Database - January, 2010
    A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn’s disease - September, 2009
    Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis - October, 2009
    Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis - November, 2009